185 related articles for article (PubMed ID: 37120736)
41. Effects of exercise training on cardiac toxicity markers in women with breast cancer undergoing chemotherapy with anthracyclines: a randomized controlled trial.
Antunes P; Joaquim A; Sampaio F; Nunes C; Ascensão A; Vilela E; Teixeira M; Capela A; Amarelo A; Marques C; Viamonte S; Alves A; Esteves D
Eur J Prev Cardiol; 2023 Jul; 30(9):844-855. PubMed ID: 36857149
[TBL] [Abstract][Full Text] [Related]
42. Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure.
Armenian SH; Hudson MM; Chen MH; Colan SD; Lindenfeld L; Mills G; Siyahian A; Gelehrter S; Dang H; Hein W; Green DM; Robison LL; Wong FL; Douglas PS; Bhatia S
BMC Cardiovasc Disord; 2016 Oct; 16(1):187. PubMed ID: 27716152
[TBL] [Abstract][Full Text] [Related]
43. Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance.
Jordan JH; D'Agostino RB; Hamilton CA; Vasu S; Hall ME; Kitzman DW; Thohan V; Lawrence JA; Ellis LR; Lash TL; Hundley WG
Circ Cardiovasc Imaging; 2014 Nov; 7(6):872-9. PubMed ID: 25273568
[TBL] [Abstract][Full Text] [Related]
44. Cardiovascular sequelae of trastuzumab and anthracycline in long-term survivors of breast cancer.
Glen C; Morrow A; Roditi G; Hopkins T; Macpherson I; Stewart P; Petrie MC; Berry C; Epstein F; Lang NN; Mangion K
Heart; 2024 Apr; 110(9):650-656. PubMed ID: 38103912
[TBL] [Abstract][Full Text] [Related]
45. Cardioprotective effect of Platycodon grandiflorum in patients with early breast cancer receiving anthracycline-based chemotherapy: study protocol for a randomized controlled trial.
Hao W; Liu S; Qin Y; Sun C; Chen L; Wu C; Bao Y
Trials; 2017 Aug; 18(1):386. PubMed ID: 28830541
[TBL] [Abstract][Full Text] [Related]
46. Relationship between regional left ventricular dysfunction and cancer-therapy-related cardiac dysfunction.
Saijo Y; Kusunose K; Okushi Y; Yamada H; Toba H; Sata M
Heart; 2020 Nov; 106(22):1752-1758. PubMed ID: 32209616
[TBL] [Abstract][Full Text] [Related]
47. Statins for Attenuating Cardiotoxicity in Patients Receiving Anthracyclines: A Systematic Review and Meta-Analysis.
Titus A; Cheema HA; Shafiee A; Seighali N; Shahid A; Bhanushali KB; Kumar A; Khan SU; Khadke S; Thavendiranathan P; Hundley WG; Scherrer-Crosbie M; Nohria A; Neilan TG; Dani SS; Nasir K; Ganatra S
Curr Probl Cardiol; 2023 Oct; 48(10):101885. PubMed ID: 37336312
[TBL] [Abstract][Full Text] [Related]
48. Long-term prognostic value of right ventricular dysfunction on cardiovascular magnetic resonance imaging in anthracycline-treated cancer survivors.
Chhikara S; Hooks M; Athwal PSS; Hughes A; Ismail MF; Joppa S; Velangi PS; Nijjar PS; Blaes AH; Shenoy C
Eur Heart J Cardiovasc Imaging; 2022 Aug; 23(9):1222-1230. PubMed ID: 34297807
[TBL] [Abstract][Full Text] [Related]
49. Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.
de Vries Schultink AHM; Boekhout AH; Gietema JA; Burylo AM; Dorlo TPC; van Hasselt JGC; Schellens JHM; Huitema ADR
J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):431-442. PubMed ID: 29429038
[TBL] [Abstract][Full Text] [Related]
50. Two-dimensional speckle tracking echocardiography help identify breast cancer therapeutics-related cardiac dysfunction.
Liu W; Li W; Li H; Li Z; Zhao P; Guo Z; Liu C; Sun L; Wang Z
BMC Cardiovasc Disord; 2022 Dec; 22(1):548. PubMed ID: 36522712
[TBL] [Abstract][Full Text] [Related]
51. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
Henriksen PA
Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634
[TBL] [Abstract][Full Text] [Related]
52. An artificial intelligence approach for predicting cardiotoxicity in breast cancer patients receiving anthracycline.
Chang WT; Liu CF; Feng YH; Liao CT; Wang JJ; Chen ZC; Lee HC; Shih JY
Arch Toxicol; 2022 Oct; 96(10):2731-2737. PubMed ID: 35876889
[TBL] [Abstract][Full Text] [Related]
53. Cardiovascular magnetic resonance characterisation of anthracycline cardiotoxicity in adults with normal left ventricular ejection fraction.
Harries I; Berlot B; Ffrench-Constant N; Williams M; Liang K; De Garate E; Baritussio A; Biglino G; Plana JC; Bucciarelli-Ducci C
Int J Cardiol; 2021 Nov; 343():180-186. PubMed ID: 34454967
[TBL] [Abstract][Full Text] [Related]
54. A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer.
Lewinter C; Nielsen TH; Edfors LR; Linde C; Bland JM; LeWinter M; Cleland JGF; Køber L; Braunschweig F; Mansson-Broberg A
Eur Heart J; 2022 Jul; 43(27):2562-2569. PubMed ID: 34951629
[TBL] [Abstract][Full Text] [Related]
55. Value of Echocardiography and Cardiac Magnetic resonance in assessing left ventricular function in breast and gastric cancer patients after Anthracycline Chemotherapy.
Jin CL; Shi XG; Wang TT; Li HW; Zhang DX; Sheng Z; Xiao J; Yu YQ
BMC Cardiovasc Disord; 2023 Sep; 23(1):465. PubMed ID: 37715125
[TBL] [Abstract][Full Text] [Related]
56. Usefulness of Integrating Heart Failure Risk Factors Into Impairment of Global Longitudinal Strain to Predict Anthracycline-Related Cardiac Dysfunction.
Milks MW; Velez MR; Mehta N; Ishola A; Van Houten T; Yildiz VO; Reinbolt R; Lustberg M; Smith SA; Orsinelli DA
Am J Cardiol; 2018 Apr; 121(7):867-873. PubMed ID: 29454478
[TBL] [Abstract][Full Text] [Related]
57. Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy.
Janbabai G; Nabati M; Faghihinia M; Azizi S; Borhani S; Yazdani J
Cardiovasc Toxicol; 2017 Apr; 17(2):130-139. PubMed ID: 27003392
[TBL] [Abstract][Full Text] [Related]
58. Early myocardial oedema can predict subsequent cardiomyopathy in high-dose anthracycline therapy.
Muehlberg F; Kornfeld M; Zange L; Ghani S; Reichardt A; Reichardt P; Schulz-Menger J
ESC Heart Fail; 2023 Feb; 10(1):616-627. PubMed ID: 36404640
[TBL] [Abstract][Full Text] [Related]
59. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.
Sawaya H; Sebag IA; Plana JC; Januzzi JL; Ky B; Tan TC; Cohen V; Banchs J; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
Circ Cardiovasc Imaging; 2012 Sep; 5(5):596-603. PubMed ID: 22744937
[TBL] [Abstract][Full Text] [Related]
60. Protective effects of Panax ginseng against doxorubicin-induced cardiac toxicity in patients with non-metastatic breast cancer: A randomized, double-blind, placebo-controlled clinical trial.
Hamidian M; Foroughinia F; Haghighat S; Attar A; Haem E
J Oncol Pharm Pract; 2023 Sep; 29(6):1306-1316. PubMed ID: 35975564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
